Home/Filings/4/A/0001209191-22-016533
4/A//SEC Filing

Lebwohl David 4/A

Accession 0001209191-22-016533

CIK 0001652130other

Filed

Mar 3, 7:00 PM ET

Accepted

Mar 4, 9:01 PM ET

Size

5.8 KB

Accession

0001209191-22-016533

Insider Transaction Report

Form 4/AAmended
Period: 2022-03-01
Lebwohl David
EVP, Chief Medical Officer
Transactions
  • Award

    Stock Option (right to buy)

    2022-03-01+20,20320,203 total
    Exercise: $79.85Exp: 2032-02-28Common Stock (20,203 underlying)
Footnotes (2)
  • [F1]The original Form 4 incorrectly reported the number of options granted as 13,816.
  • [F2]This option was granted on March 1, 2022 with respect to shares of Common Stock, with 33% vesting on January 1, 2023 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.

Issuer

Intellia Therapeutics, Inc.

CIK 0001652130

Entity typeother

Related Parties

1
  • filerCIK 0001810882

Filing Metadata

Form type
4/A
Filed
Mar 3, 7:00 PM ET
Accepted
Mar 4, 9:01 PM ET
Size
5.8 KB